• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs).新型羟苯甲酮负载纳米结构脂质载体(NLCs)的配方。
AAPS PharmSciTech. 2010 Dec;11(4):1684-94. doi: 10.1208/s12249-010-9553-2. Epub 2010 Nov 24.
2
Preparation and characterization of oxybenzone-loaded solid lipid nanoparticles (SLNs) with enhanced safety and sunscreening efficacy: SPF and UVA-PF.具有更高安全性和防晒功效(防晒系数和UVA防护因子)的氧苯酮负载型固体脂质纳米粒的制备与表征
Drug Discov Ther. 2010 Dec;4(6):472-83.
3
Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).基于质量源于设计(QbD)理念开发的醋氯芬酸纳米结构脂质载体(NLCs):改善炎症性疾病的皮肤动力学特征。
Int J Pharm. 2017 Jan 30;517(1-2):413-431. doi: 10.1016/j.ijpharm.2016.12.010. Epub 2016 Dec 9.
4
Nanostructured lipid carriers for the topical delivery of tretinoin.用于维甲酸局部递送的纳米结构脂质载体。
Eur J Pharm Biopharm. 2016 Nov;108:253-261. doi: 10.1016/j.ejpb.2016.07.026. Epub 2016 Aug 9.
5
Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.系统实施质量源于设计(QbD)以开发用于眼部应用的载 NSAID 的纳米结构化脂质载体:制剂前筛选研究和统计混合设计优化变量。
Drug Dev Ind Pharm. 2020 Mar;46(3):443-455. doi: 10.1080/03639045.2020.1724135. Epub 2020 Feb 9.
6
Preparation and characterization of oxybenzone-loaded gelatin microspheres for enhancement of sunscreening efficacy.用于增强防晒功效的氧苯酮负载明胶微球的制备与表征
Drug Deliv. 2006 Sep-Oct;13(5):323-30. doi: 10.1080/10717540500398175.
7
Topical phenytoin nanostructured lipid carriers: design and development.局部用苯妥英纳米结构脂质载体:设计与开发
Drug Dev Ind Pharm. 2018 Jan;44(1):144-157. doi: 10.1080/03639045.2017.1386204. Epub 2017 Oct 17.
8
Fabrication of Mupirocin-Loaded Nanostructured Lipid Carrier and Its Characterization.莫匹罗星负载纳米结构脂质载体的制备及其表征。
Assay Drug Dev Technol. 2021 May-Jun;19(4):216-225. doi: 10.1089/adt.2020.1070. Epub 2021 Mar 30.
9
Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification.通过熔融乳化法制备用于控释孕酮的纳米结构脂质载体及其特性
Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):174-9. doi: 10.1016/j.colsurfb.2007.06.011. Epub 2007 Jun 16.
10
Ursolic acid rich Ocimum sanctum L leaf extract loaded nanostructured lipid carriers ameliorate adjuvant induced arthritis in rats by inhibition of COX-1, COX-2, TNF-α and IL-1: Pharmacological and docking studies.熊果酸富集的神圣罗勒(Ocimum sanctum L.)叶提取物负载的纳米结构脂质载体通过抑制 COX-1、COX-2、TNF-α 和 IL-1 改善大鼠佐剂性关节炎:药理学和对接研究。
PLoS One. 2018 Mar 20;13(3):e0193451. doi: 10.1371/journal.pone.0193451. eCollection 2018.

引用本文的文献

1
In-situ Nanolipoidal Gel of Stiripentol for Intranasal Administration: Preclinical Evidence of Enhanced Biopharmaceutical and Therapeutic Outcomes.用于鼻腔给药的司替戊醇原位纳米脂质凝胶:生物药剂学和治疗效果增强的临床前证据
AAPS PharmSciTech. 2025 Aug 25;26(7):220. doi: 10.1208/s12249-025-03209-1.
2
Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles.用于增强载依巴斯汀固体脂质纳米粒递送的口腔崩解膜的开发与优化
Int J Nanomedicine. 2025 May 30;20:6963-6981. doi: 10.2147/IJN.S521504. eCollection 2025.
3
Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.基于脂质的纳米制剂在甲癣治疗中的应用:应对当前治疗的挑战并推进治疗进展
RSC Adv. 2025 Mar 11;15(10):7799-7825. doi: 10.1039/d5ra00387c. eCollection 2025 Mar 6.
4
The Tiny Big Difference: Nanotechnology in Photoprotective Innovations - A Systematic Review.《微中见大:光防护创新中的纳米技术——系统评价》。
AAPS PharmSciTech. 2024 Sep 7;25(7):212. doi: 10.1208/s12249-024-02925-4.
5
Formulation and Characterization of Mupirocin Nanomicelles in Insulin-Based Gel for Dermatological Application.用于皮肤科应用的基于胰岛素的凝胶中莫匹罗星纳米胶束的配方与表征
J Pharm Bioallied Sci. 2023 Jul;15(Suppl 2):S1178-S1181. doi: 10.4103/jpbs.jpbs_172_23. Epub 2023 Jul 11.
6
Clinical Applications of Sunscreens and Formulation Advancements.防晒霜的临床应用和配方进展。
Curr Drug Res Rev. 2024;16(2):198-208. doi: 10.2174/2589977515666230718124841.
7
Nanogel Containing Gamma-Oryzanol-Loaded Nanostructured Lipid Carriers and TiO/MBBT: A Synergistic Nanotechnological Approach of Potent Natural Antioxidants and Nanosized UV Filters for Skin Protection.含有γ-谷维素负载纳米结构脂质载体和TiO/MBBT的纳米凝胶:一种用于皮肤保护的强效天然抗氧化剂和纳米级紫外线过滤器的协同纳米技术方法。
Pharmaceuticals (Basel). 2023 Apr 28;16(5):670. doi: 10.3390/ph16050670.
8
Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment.纳米颗粒作为皮肤癌预防和治疗的治疗递送系统。
JID Innov. 2023 Mar 16;3(4):100197. doi: 10.1016/j.xjidi.2023.100197. eCollection 2023 Jul.
9
Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity.纳米结构脂质载体中阿哌沙班的定制化:提高其口服生物利用度及抗凝活性
Pharmaceutics. 2022 Dec 27;15(1):80. doi: 10.3390/pharmaceutics15010080.
10
Cod liver oil nano-structured lipid carriers (Cod-NLCs) as a promising platform for nose to brain delivery: Preparation, optimization, cytotoxicity & biodistribution utilizing radioiodinated zopiclone.鳕鱼肝油纳米结构脂质载体(Cod-NLCs)作为一种有前景的鼻脑给药平台:利用放射性碘化佐匹克隆进行制备、优化、细胞毒性及生物分布研究
Int J Pharm X. 2023 Jan 4;5:100160. doi: 10.1016/j.ijpx.2023.100160. eCollection 2023 Dec.

本文引用的文献

1
Molecular interaction and localization of tocotrienol-rich fraction (TRF) within the matrices of lipid nanoparticles: evidence studies by Differential Scanning Calorimetry (DSC) and Proton Nuclear Magnetic Resonance spectroscopy ((1)H NMR).生育三烯酚富集物(TRF)在脂质纳米粒基质中分子相互作用和定位的研究:差示扫描量热法(DSC)和质子核磁共振波谱(1H NMR)的证据研究。
Colloids Surf B Biointerfaces. 2010 Jun 1;77(2):286-97. doi: 10.1016/j.colsurfb.2010.02.003. Epub 2010 Feb 11.
2
Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.亲脂性乳化剂对纳米结构脂质载体中洛伐他汀口服给药的影响:理化特性和药代动力学。
Eur J Pharm Biopharm. 2010 Mar;74(3):474-82. doi: 10.1016/j.ejpb.2009.12.008. Epub 2010 Jan 7.
3
Formulation and characterization of bufadienolides-loaded nanostructured lipid carriers.载蟾毒内酯纳米结构脂质载体的制备及表征。
Drug Dev Ind Pharm. 2010 May;36(5):508-17. doi: 10.3109/03639040903264397.
4
Solid lipid nanoparticles and nanoemulsions containing ceramides: preparation and physicochemical characterization.含神经酰胺的固体脂质纳米粒和纳米乳剂:制备及理化特性研究
J Liposome Res. 2009;19(3):180-8. doi: 10.1080/08982100802702046.
5
Q10-loaded NLC versus nanoemulsions: stability, rheology and in vitro skin permeation.负载Q10的纳米脂质载体与纳米乳剂:稳定性、流变学及体外皮肤渗透
Int J Pharm. 2009 Jul 30;377(1-2):207-14. doi: 10.1016/j.ijpharm.2009.05.020. Epub 2009 May 22.
6
Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.脂质核材料对用于口服淋巴递送的固体脂质纳米粒特性的影响。
Nanomedicine. 2009 Jun;5(2):184-91. doi: 10.1016/j.nano.2008.08.003. Epub 2008 Dec 17.
7
Novel self-assembled amphiphilic poly(epsilon-caprolactone)-grafted-poly(vinyl alcohol) nanoparticles: hydrophobic and hydrophilic drugs carrier nanoparticles.新型自组装两亲性聚(ε-己内酯)接枝聚(乙烯醇)纳米粒子:疏水性和亲水性药物载体纳米粒子
J Mater Sci Mater Med. 2009 Mar;20(3):821-31. doi: 10.1007/s10856-008-3637-5. Epub 2008 Nov 20.
8
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products.用于化妆品和药品皮肤产品中的脂质纳米颗粒(固体脂质纳米粒、纳米结构脂质载体)
Int J Pharm. 2009 Jan 21;366(1-2):170-84. doi: 10.1016/j.ijpharm.2008.10.003. Epub 2008 Oct 17.
9
Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil.一种化学敏感型氮芥衍生物:苯丁酸氮芥脂质纳米粒的制剂与药代动力学
Int J Pharm. 2009 Feb 9;367(1-2):187-94. doi: 10.1016/j.ijpharm.2008.09.032. Epub 2008 Sep 26.
10
Experimental design for the optimization of lipid nanoparticles.用于优化脂质纳米颗粒的实验设计
J Pharm Sci. 2009 May;98(5):1813-9. doi: 10.1002/jps.21549.

新型羟苯甲酮负载纳米结构脂质载体(NLCs)的配方。

Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs).

机构信息

Department of Pharmaceutics, National Organization of Drug Control and Research (NODCAR), Cairo, Egypt.

出版信息

AAPS PharmSciTech. 2010 Dec;11(4):1684-94. doi: 10.1208/s12249-010-9553-2. Epub 2010 Nov 24.

DOI:10.1208/s12249-010-9553-2
PMID:21107771
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3011069/
Abstract

The objective of the current study was to formulate oxybenzone into nanostructured lipid carriers (NLCs) to enhance its sunscreening efficacy and safety. NLCs of oxybenzone were prepared by the solvent diffusion method. A complete 2(3) factorial design was used for the evaluation of the prepared oxybenzone NLCs. The study design involves the investigation of the effect of three independent variables namely liquid lipid type (Miglyol 812 and oleic acid), liquid lipid concentration (15% and 30%), and oxybenzone concentration (5% and 10% with respect to total lipids) on the particle size (p.s.) , the entrapment efficiency (EE%) and the in vitro drug release after 8 h. The prepared NLCs were spherical in overall shape and were below 0.8 microm. Miglyol 812 and 30% liquid lipid were found to significantly decrease the p.s. and increase the EE% when compared to oleic acid and 15% liquid lipid. Increasing oxybenzone concentration increased significantly the p.s. but did not affect the EE%. NLCs prepared using Miglyol 812, 15% liquid lipid, and 10% oxybenzone showed slower drug release when compared to those prepared using oleic acid, 30% liquid lipid, and 5% oxybenzone, respectively. The candidate oxybenzone-loaded NLC dispersion was then formulated into gel. The incorporation of oxybenzone into NLCs greatly increased the in vitro sun protection factor and erythemal UVA protection factor of oxybenzone more than six- and eightfold, respectively, while providing the advantage of overcoming side effects of free oxybenzone as evidenced by very low irritation potential.

摘要

本研究的目的是将氧苯酮制成纳米结构脂质载体(NLC),以提高其防晒效果和安全性。通过溶剂扩散法制备氧苯酮 NLC。采用完全 2(3)析因设计评价所制备的氧苯酮 NLC。研究设计包括考察三种独立变量(液体脂质类型(Migl yol 812 和油酸)、液体脂质浓度(15%和 30%)和氧苯酮浓度(分别相对于总脂质为 5%和 10%)对粒径(p.s.)、包封效率(EE%)和 8 小时后体外药物释放的影响。所制备的 NLC 总体呈球形,粒径小于 0.8 微米。与油酸和 15%液体脂质相比,Migl yol 812 和 30%液体脂质显著降低了 p.s.,并提高了 EE%。增加氧苯酮浓度显著增加了 p.s.,但对 EE%没有影响。与分别使用油酸、30%液体脂质和 5%氧苯酮制备的 NLC 相比,使用 Migl yol 812、15%液体脂质和 10%氧苯酮制备的 NLC 显示出较慢的药物释放。然后将候选氧苯酮负载的 NLC 分散体制成凝胶。将氧苯酮掺入 NLC 中,使氧苯酮的体外防晒因子和红斑 UVA 保护因子分别增加了六倍和八倍以上,同时提供了克服游离氧苯酮副作用的优势,这从极低的刺激性潜力得到证明。